EXEL earnings analysis
What we found in EXEL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Exelixis reported strong first-quarter results for 2026, with total revenues of $610.8 million, surpassing expectations, and a diluted EPS of $0.79, reflecting solid growth driven by increasing demand for its cabozantinib franchise. The company's net product revenues increased by 8% year-over-year, buoyed by a rise in sales volume, while expenses saw a decrease, leading to improved profitability.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surge Above Estimates
- Total revenues reached $610.8 million in Q1 2026, up 10% from $555.4 million in Q1 2025, exceeding the estimate of $606.4 million.
- Strong EPS Growth
- Diluted EPS increased to $0.79 in Q1 2026 from $0.55 in Q1 2025, surpassing the expected $0.74.
- Increase in Net Product Revenues
- Net product revenues rose to $555 million, an 8% increase from $513.3 million in the prior year.
- Cash Flow from Operations Increases
- Net cash provided by operating activities grew by 19%, reaching $251.8 million compared to $211.4 million in the prior period.
- Decreased R&D Expenses
- Research and development expenses dropped to $199.9 million, down 6% from $212.2 million in Q1 2025.
- Share Repurchase Program Continuing
- As of March 31, 2026, Exelixis completed $590.6 million in share repurchases and authorized an additional $750 million for future buybacks.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory Approval Risks Persist
- Continued success hinges on the FDA approval of zanzalintinib, which is under review, with a PDUFA date of December 3, 2026.
- Increasing Competition Looms
- Generic versions of CABOMETYX face potential entry, which could significantly impact revenues.
- Reimbursement Pressure
- Ongoing changes in U.S. healthcare policies may affect coverage and payment for CABOMETYX, impacting sales.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.79
- Gross margin
- 96%
- Segment
- Net product revenues
- Segment
- License revenues
- Segment
- Collaboration services revenues
What they said about what is next.
Maintained 2026 revenue guidance of $2.525B to $2.625B, continuing strong expectations despite potential headwinds.
The filing reads better than the one before it.
What came before.
- 10-K · February 10, 2026
- Exelixis positions itself as a cabozantinib-focused oncology company leveraging strong commercial momentum in CABOMETYX/COMETRIQ while advancing a diversified pipeline led by zanzalintinib (currently under FDA review).…
- 10-Q · July 28, 2025
- Exelixis reported Q2 revenues of $568,261,000 and diluted EPS of $0.65 for the three months ended June 30, 2025. Results were driven by higher net product sales (cabozantinib) but offset by a sharp decline in…
- 10-Q · May 13, 2025
- Exelixis reported strong Q1 results with revenues of $555.447M and operating income of $186.859M, driven by CABOMETYX product sales of $510.872M. Operating margin expanded to ~33.6% and diluted EPS was $0.55; operating…
- 10-K · February 11, 2025
- Exelixis remains a cabozantinib‑focused oncology company with strong 2024 commercial performance (net product revenues of $1,809.4 million, ~11% YoY) and its eighth consecutive year of profitability. The company is…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EXEL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever